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Abstract 
Background: 
Glaucoma is a leading cause of irreversible blindness involving loss of retinal ganglion cells 
(RGC). Mesenchymal stromal/stem cells (MSC) have shown promise as a paracrine-
mediated therapy for compromised neurons. It is however unknown if dental pulp stem cells 
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(DPSC) are effective as a cellular therapy in glaucoma and how their hypothesised influence 
compares to other more widely researched MSC sources. The present study aimed to 
compare the efficacy of adipose-derived stem cells, bone marrow-derived mesenchymal 
stem cells (BMSC) and DPSC in preventing the loss of RGC and visual function when 
transplanted into the vitreous of glaucomatous rodent eyes. 
Methods: 
Thirty five days after raised intraocular pressure (IOP) and intravitreal stem cell 
transplantation, Brn3a+ RGC numbers, retinal nerve fibre layer thickness (RNFL) and RGC 
function were evaluated by immunohistochemistry (IHC), optical coherence tomography 
(OCT) and electroretinography (ERG), respectively.  
Results: 
Control glaucomatous eyes that were sham-treated with heat killed DPSC had a significant 
loss of RGC numbers, RNFL thickness and function compared with Intact eyes. BMSC and, 
to a greater extent, DPSC provided significant protection from RGC loss, RNFL thinning and 
preserved RGC function.  
Discussion: 
The study supports the use of DPSC as a neuroprotective cellular therapy in retinal 
degenerative disease such as glaucoma. 
Key words: Stem cell transplantation, Glaucoma, Dental pulp stem cells, Mesenchymal 
stem cells, Neuroprotection, Retinal ganglion cells 
Abbreviations: ADSC, adipose-derived mesenchymal stem cells; ADB, antibody diluting 
buffer; ANOVA, one-way analysis of variance; BDNF, brain-derived neurotrophic factor; 
BMSC, bone marrow-derived mesenchymal stem cells; BSA, bovine serum albumin; CNS, 
central nervous system; d, days; DPSC, dental pulp stem cells; ERG, electroretinogram; 
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FBS, foetal bovine serum; h, hours; IC, intracameral; IOP, intraocular pressure; ivit, 
intravitreal; min, minutes; MSC, mesenchymal stem cells; NGF, nerve growth factor; NT-3, 
neurotrophin-3; NTF, neurotrophic factors; OCT, optical coherence tomography, PBS, 
phosphate-buffered saline; PFA, paraformaldehyde; PDGF, platelet-derived growth factor; 
pSTR, positive scotopic threshold response; RGC, retinal ganglion cells; RNFL, retinal nerve 
fibre layer; RT, room temperature; SEM, standard error of the mean; TGF-β, transforming 
growth factor-beta. 
 
1 Introduction 
Glaucoma is a common cause of irreversible blindness and is characterised by a 
degenerative loss of retinal ganglion cells (RGC) and their axons, leading to optic disc 
cupping and reduced visual acuity(1). Current treatments are designed to reduce intraocular 
pressure (IOP) to slow disease progression whereas neuroprotective treatments that directly 
target the injured RGC are still in their infancy. Neurotrophic factors (NTF), in particular 
neurotrophins, are neuronal survival factors that are retrogradely transported along a 
functionally connected axon to the soma maintaining the survival of connected neurons, but 
unconnected neurons die by apoptosis(2). Elevation of IOP significantly inhibits retrograde 
transport of NTF (3) and is one of the mechanisms involved in RGC death(4). NTF, 
especially when delivered in combinations, promote the survival of injured RGC in vitro(5, 6). 
However their neuroprotective efficacy in vitro is not easily translatable to in vivo models as 
a constant delivery of multiple NTF is required for maintaining therapeutic effect(7, 8). 
Mesenchymal stromal/stem cells (MSC) are multipotent self-replicating stromal cells are 
being evaluated as a cellular therapy for treating glaucoma based on their secretion of a 
wide array of NTF(9-12). MSC-derived NTF protect injured RGC, protecting them from death 
and ultimately preserving vision(13) and several clinical trials evaluating their 
neuroprotective efficacy are ongoing(14). MSC can be isolated from a variety of adult tissues 
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such as bone marrow (BMSC) and adipose tissue (ADSC) but here we have focused on the 
use of MSC-like cells from the dental pulp (DPSC). DPSC are multipotent cranial neural 
crest-derived stem cells(15, 16) that secrete significantly more NTF, including nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) than 
ADSC and BMSC(9, 10). We and others have demonstrated significant RGC 
neuroprotection by DPSC(9) and BMSC(17, 18) after traumatic optic neuropathy and shown 
in vitro that this neuroprotective effect is most likely due to NTF, including neurotrophins(9, 
10) and platelet-derived growth factor (PDGF)(12). These findings indicated that MSC, and 
in particular DPSC, may be more effective as a treatment for neurodegenerative conditions 
such as glaucoma. 
We have demonstrated a significantly greater neuroprotective effect of DPSC compared to 
BMSC/ADSC in an in vitro model of RGC injury, with multiple secreted NTF being the 
mechanism behind the effect(10). We now hypothesise that DPSC may also be a candidate 
cellular therapy for protecting RGC from loss in glaucoma and determined to test this using 
an in vivo model. Accordingly, three widely researched stem cells for ocular repair(14), 
BMSC, ADSC and DPSC were transplanted into the vitreous body of rats in which ocular 
hypertension was induced using exogenously administered transforming growth factor-β1 
(TGF-β). Administration of TGF- β1(19) or TGF- β2(20, 21) are both accepted models that 
induce sustained elevations in IOP leading to significant RGC loss. In this study RGC 
survival was assessed using immunohistochemical quantification of Brn3+ RGC and retinal 
imaging using optical coherence tomography (OCT) of the retinal nerve fibre layer (RNFL) 
thickness.  Changes in retinal function were measured using electroretinography (ERG). 
2 Materials and Methods 
All reagents were purchased from Sigma (Poole, UK) unless otherwise specified. 
2.1 Human (h)DPSC/BMSC/ADSC cultures 
5 
 
hDPSC were obtained from AllCell LLC (Berkeley, CA) and both hBMSC and hADSC from 
Lonza (Slough, UK), Each MSC batch represented pooled samples from 3 donors. The MSC 
were characterised by CD29+/CD44+/CD73+/CD90+/CD45- profile confirmed by the supplier) 
and demonstrated multi-differentiation (osteogenic, adipogenic and chondrogenic) capability. 
The stem cells were cultured  into T25/T75 flasks (Corning, Amsterdam, NL) in both a total 
volume of 5ml/15ml DMEM containing 1% penicillin/streptomycin and 10% foetal bovine 
serum (FBS; Hyclone Laboratories, Logan, UT) and at a density of 1x106 cells/2x106 cells, 
respectively. Cultures were maintained at 37°C in 5% CO2, the supplemented medium was 
changed every 3d and the cells were passaged when 80% confluent using 0.05% 
trypsin/EDTA. One week before transplantation, cells were transfected with a gfp plasmid 
using lipofectamine 3000 (Life Technologies, Invitrogen, Paisley, UK) according to the 
manufacturer’s protocol. This study used MSC at passage 2-4, when 80% confluent and with 
no observable physical differences between the 3 cell types. 
2.2 Experimental design 
Twelve rats (24 eyes) received bi-weekly (twice a week) bilateral intracameral (IC) injections 
of TGF-β0-35d (for 5 weeks) and were separated into 2 groups of 6. On 0d, Group 1 received 
an ivit transplantation of DPSC into one eye and dead DPSC (sham control) into the other 
eye (left and right eyes, respectively, in 3 rats, and vice versa in the remaining 3 rats). On 
0d, Group 2 received an ivit transplantation of BMSC into one eye and ADSC into the other 
eye (left and right eyes, respectively, in 3 rats, and vice versa in the remaining 3 rats). All 
rats in Group 1 and 2 received ERG and OCT recordings on 35d, before culling and tissue 
processing for immunohistochemistry. Animal numbers in each group were determined using 
a previously published power calculation(22, 23). A separate group of 6 rats received bi-
weekly unilateral IC injections of PBS0-35d and these rats are referred to as the Intact Group.  
2.3 Animals 
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All animal procedures were performed in strict accordance to the UK Home Office Animals 
Scientific Procedures Act, 1986, and approved by the University of Birmingham Ethical 
Review Sub-Committee. Eighteen adult female Sprague Dawley rats weighing 150-200g 
(Charles River, Margate, UK) were housed in conditions of 21°C and 55% humidity under a 
12h light/dark cycle with a daytime luminance of 80 lux, given food/water ad libitum and were 
monitored by welfare staff. Gaseous anaesthesia was induced with 5% Isoflurane/1.5L per 
minute O2 (National Veterinary Supplies, Stoke, UK) and maintained at 3.5% during surgery 
and 2% during ERG recording. 
2.4 Surgery for IC injections to induce ocular hypertension and ivit transplantation of 
MSC 
Following anaesthetic induction, IOP were recorded for all rats using an icare tonometer 
(Tonolab, Helsinki, Finland). Rats were then secured in a head-holding frame for IC 
injections of TGF-β1 (Peprotech, London, UK) through a single corneal incision, 2mm 
anterior to the limbus using a 15° blade (BD Ophthalmic System, Warwickshire, UK). Using 
the same incision site a glass micropipette, produced in-house from a glass capillary rod 
(Harvard Apparatus, Kent, UK) using a Flaming-Brown micropipette puller (Sutter 
Instruments, Novato, CA) was used to inject 3.5µl of 5µg/ml activated TGF-β1 IC into all 12 
rats. Contemporaneously, while the animals were still anaesthetised, a glass micropipette 
preloaded with 150,000 MSC suspended in 5µl of PBS, was used to inject living or dead 
cells (killed by heating for 30min at 80°C), into the vitreous of the eye (Fig. 1). A cell dosage 
of 150,000 was the maximum number of cells that could be suspended in 5µl while still 
allowing easy passage through the fine tip of the glass micropipette. After surgery, animals 
were placed in warm recovery cages and monitored for recovery of normal behaviour before 
being returned to their home cages. IOP recordings and IC injections of TGF-β were 
repeated bi-weekly0-35d throughout the study. A separate 6 rats (Intact Group) received bi-
weekly0-35d IC injections of PBS alone. 
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2.5 Optical coherence tomography (OCT) of retinal nerve fibre layer 
OCT allows in vivo measuring of retinal thickness with RNFL being a surrogate measure of 
RGC density. OCT retinal nerve fibre layer analysis was performed at 35d on all rats while 
under inhalation anaesthesia using a Spectralis HRA3 confocal scanning laser 
ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany). OCT images were taken 
of the retina around the optic nerve head and the in-built software was used to segment the 
images and quantify the RNFL thickness.  
2.6 Electroretinography 
ERG records the electrical function of retina in response to a known intensity of light, with 
different intensities eliciting responses in different retinal cell populations. By eliciting a RGC 
dependant response, visual function of the glaucomatous rats can be assessed. ERG 
(HMsERG; Ocuscience, Kansas City, MO) were recorded at 35d. Rats were dark adapted 
for 12 hours overnight and prepared for ERG recording under dim red light (>630nm). 
Scotopic flash ERG were recorded from -5.5 to +1  log units with respect to standard flash in 
half log-unit steps, using DTL fiber (Unimed Electrode Supplies, Farnham, UK) corneal 
electrodes with pressure-molded Aclar contact lenses and needle skin recording electrodes 
(Unimed Electrode Supplies).  
2.7 ERG analysis 
By analysing the amplitude of the ERG trace, the visual function of the rat can be quantified. 
ERG traces were analysed using ERGVIEW (Ocuscience). Oscillatory potentials were 
removed by filtering waveforms above 20Hz from the trace before analysis. Traces at a light 
intensity of 1 and 3 mcd/s were chosen for analysis as they gave a clean, unambiguous 
positive scotopic threshold response (pSTR) with a mean latency of 100ms. The amplitude 
of the pSTR was measured from baseline. A representative, unfiltered trace is shown in 
Figure 5C. 
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2.8 Tissue preparation 
Rats were given an intraperitoneal injection of 1ml sodium pentobarbital (National Veterinary 
Supplies) at 35d and perfused intracardially with 4% paraformaldehyde (PFA; TAAB, 
Reading, UK) in PBS while under terminal anaesthesia. Eyes were removed and immersion 
fixed in 4% PFA in PBS for 2h at 4°C before cryoprotection in 10%, 20% and 30% sucrose 
solution in PBS for 24h with storage at 4°C. Eyes were then embedded using optimal cutting 
temperature embedding medium (Thermo Shandon, Runcorn, UK) in peel-away mould 
containers (Agar Scientific, Essex, UK) by rapid freezing under crushed dry ice and stored at 
-80°C. After embedding, eyes were sectioned on a cryostat microtome (Bright, Huntingdon, 
UK) at -22°C at a thickness of 20 µm and mounted on positively charged glass slides 
(Superfrost Plus, Fisher Scientific, Pittsburgh, PA). Radial eye sections were left to dry on 
slides overnight at 37°C before storage at -20°C. Standard eye sections containing the optic 
nerve head were used to account for variation in RGC density. 
2.9 Immunohistochemistry 
Mounted tissue sections were equilibrated to room temperature (RT), hydrated in PBS for 2 
X 5min, permeabilized in 0.1% triton x-100 in PBS for 20min at RT and washed for 2 X 5min 
in PBS before isolation with a hydrophobic PAP pen (Immedge pen; Vector Laboratories, 
Peterborough, UK). Non-specific protein binding sites in sections were blocked by incubation 
in blocking buffer (75µl; 0.5% bovine serum albumin (g/ml), 0.3% Tween-20, 15% normal 
goat/donkey serum (Vector Laboratories) in PBS) in a humidified chamber for 30min at RT 
and then sections were drained and incubated with either Brn3a primary antibody (1:200; 
Santa Cruz, CA, #SC-31984) or Stro1 primary antibody (1:100; R&D Systems, MN, 
#MAB1038) diluted in antibody diluting buffer (ADB; 0.5% bovine serum albumin, 0.3% 
Tween-20 in PBS) overnight at 4°C. The following day, slides were washed for 3 X 5min in 
PBS. Tissue sections were then incubated with Goat IgG Alexa 594 secondary antibody 
(1:400; Molecular Probes, Paisley, UK; #A-11058) diluted in ADB for 1h in a hydrated 
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incubation chamber at RT. After 1h, slides were washed for 3 X 5min in PBS, mounted in 
Vectorshield mounting medium containing DAPI (Vector Laboratories) and stored at 4°C 
before microscopic analysis. 
2.10 Microscopy and analysis 
Fluorescently stained sections were analysed by an operator blinded to treatment groups, 
using a Zeiss Axioplan-2 fluorescent microscope (Carl Zeiss Ltd, Hertfordshire, UK). For 
immunohistochemistry, Brn3a+ RGC were counted in 20µm thick standard sections of the 
retina, along a 250µm linear region of the ganglion cell layer either side of the optic nerve, as 
described previously(22). Four sections per retina and 6 retinae from 6 different animals per 
treatment group were quantified. 
2.11 Statistics 
All statistical tests were performed using SPSS 17.0 (IBMM SPSS, Inc., Chicago, IL) and 
data were presented as mean ± standard error of the mean (SEM). The Shapiro-Wilk test 
was used to ensure all data were normally distributed before parametric testing.  IOP data 
were measured using the generalised estimated equations (autoregressive correlation 
matrix). RGC survival and function data were tested for significance using 1-way ANOVA for 
>2 group comparisons ± SEM and Tukey post-hoc test. Statistical difference was considered 
significant at p values < 0.05. 
3 Results 
3.1 IC injections of TGF-β significantly raised IOP over 35d 
IC injections of TGF-β induced a significant increase in IOP by 7d (16.9 ± 2.3mmHg) 
compared to Intact (PBS injected) eyes (10.2 ± 0.7mmHg) which was maintained between 
14d (13.8 ± 0.7mmHg) and 35d (13.9 ± 0.9mmHg) compared to PBS (9.3 ± 0.2mmHg and 
11.4 ± 1.1mmHg, respectively; Fig. 2). No significance differences were seen at 3d and 10d. 
IOP measurements between the four separate MSC treatment groups IC injected with TGF-
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β were not significantly different from each other at any time point (not shown). These data 
show that IC TGF-β injections raised IOP and that IOP was not affected by the IC injection of 
stem cells.  
3.2 MSC protected eyes from elevated IOP-induced RNFL thinning  
The RNFL comprises axons belonging to the RGC and is lost concomitantly with the loss of 
the RGC cell body. TGF-β-induced elevations in IOP led to a significant RNFL thinning by 
35d (27.0 ± 1.8µm) compared to Intact controls (55.5 ± 0.6µm; Fig. 3). Intravitreal (ivit) 
transplantation of both BMSC and, to a greater degree, DPSC, preserved RNFL thickness 
(37.3 ± 0.6µm and 41.3 ± 1.3µm, respectively) compared to sham-treated (dead DPSC 
transplanted) eyes (27.0 ± 1.8µm). Ivit transplantation of ADSC did not affect IOP-induced 
loss of RNFL thickness (29 ± 0.8µm) compared to sham-treated eyes (27.0 ± 1.8µm). RNFL 
thickness in Intact eyes was significantly greater than the RNFL thickness in all 
treated/sham-treated eyes. 
3.3 MSC protected eyes from elevated IOP-induced loss of RGC 
TGF-β-mediated elevations in IOP induced a significant 33% loss of RGC by 35d (49.0 ± 
1.6/mm of retina; sham-treated group) compared to Intact controls (73.2 ± 2.5/mm of retina; 
Fig. 4). Ivit transplantation of both BMSC and to a greater degree, DPSC, protected against 
this RGC loss and thus exhibited greater numbers of RGC (60.2 ± 1.3/mm of retina and 69.7 
± 1.9/mm of retina, respectively) compared with sham-treated eyes (49.0 ± 1.6/mm of 
retina). DPSC-induced RGC survival was significantly greater than that achieved by BMSC. 
Notably, RGC numbers in the DPSC treatment group was not different from RGC numbers 
in Intact healthy eyes. Interestingly, Ivit transplantation of ADSC did not affect RGC survival 
(52.8 ± 1.9/mm of retina) compared with sham-treated eyes (49.0 ± 1.6µm/mm of retina). 
GFP+/Stro1+ MSC were detectable on the vitreal side of the inner limiting membrane in all 
animals at select regions throughout the eye (Fig. 4B). No evidence of migration into the 
retina was seen. 
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3.4 MSC protected eyes from elevated IOP-induced loss of RGC function 
The pSTR represents the compound action potentials of RGC in response to the light 
dependant electrochemical signal originating from photoreceptors and thus its amplitude 
provides a read out of RGC function. TGF-β-mediated elevations in IOP induced a 
significant 85% loss of pSTR amplitude by 35d (21.2 ± 11.8µv) compared to Intact controls 
(140.8 ± 6.3µv; Fig. 5A). Ivit transplantation of both BMSC and to a greater degree, DPSC, 
protected against the RGC dysfunction associated with raised IOP and thus promoted 
greater preservation of pSTR (60.5 ± 18.3µv and 75.5 ± 17.4µv, respectively) compared to 
ADSC/sham-treated eyes (25.3 ± 7.8µv/21.2 ± 11.8µv, respectively), although this was only 
statistically different  for DPSC treated eyes. 
Recordings at a light intensity stimulus of 1000mcd/s as opposed to 3000mcd/s gave lower 
recordings of amplitude but the same relative differences (Fig. 5B) 
4 Discussion 
This study demonstrates for the first time that in a model of open angle glaucoma, DPSC 
promotes neuroprotection of injured RGC following ivit transplantation, preserving both their 
Brn3a+ cell body within the ganglion cell layer, axons within the RNFL and electrical function 
as measured using ERG. Of note DPSC had the greatest therapeutic effect for RGC in this 
model of glaucoma whereas ADSC had the least. DPSC thus represent a potential effective 
cellular neuroprotective therapy for glaucoma patients. 
Open angle glaucoma is the most common form of glaucoma and is characterised by 
elevated IOP related to trabecular meshwork fibrosis that perturbs the aqueous outflow 
pathway, as opposed to physical obstruction of the pathway by the iris i.e. angle closure 
glaucoma. The TGF-β model of glaucoma used in this study is based on the observation that 
patients with open angle glaucoma have elevated levels of TGF-β in the aqueous 
humour(24). This, coupled with the observations that TGF-β is a potent pro-fibrotic cytokine 
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and that fibrosis of the trabecular meshwork is a pathology that underpins the elevation in 
IOP in open angle glaucoma, makes this model a suitable representation of the human 
pathology. As seen in previous studies both from our laboratory and others(20, 21), TGF-β 
induced a reliable chronic rise in IOP and thus may be considered a suitable model to test 
neuroprotective cellular therapies relevant to glaucomatous RGC loss. 
Our findings are consistent with our previous study that showed DPSC to be RGC 
neuroprotective in an optic nerve crush injury model(9). Optic nerve crush causes a rapid 
loss of RGC with approximately 90% dead by 3 weeks. DPSC promoted some 
neuroprotection of RGC when ivit transplanted, however, there was still approximately 60% 
RGC death after complete RGC axotomy. We postulated that the slow consistent release of 
NTF from MSC, would be better suited as a therapy for a chronic neurodegenerative 
condition, such as glaucoma where the retrogradle NTF supply is attenuated but still 
present, as opposed to an acute traumatic condition such as traumatic optic neuropathy, 
where the retrogradle NTF supply is completely ablated. 
The present study is the first to demonstrate both the potential of DPSC to treat 
glaucomatous eyes and also to show that their therapeutic neuroprotective effect is 
significantly greater than BMSC and ADSC transplantation. RGC survival increased from 
67% after treatment with dead DPSC to 95% after treatment with living DPSC; notably a 
RGC count not significantly different from that in Intact animals. This result corroborates the 
neuroprotective effects observed after optic nerve crush(9), as well as in transplantation 
studies after spinal cord injury in the rat(25), both of which demonstrated that DPSC 
promoted greater neuronal survival than BMSC. Similar to the studies described above, we 
also found that the transplanted GFP+ MSC (stained for the MSC marker Stro1) survived 
within the vitreous space for the full length of the study with no evidence of migration into 
retinal tissue (Fig. 4B). 
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Previous studies by Johnson et al, have explored the use of BMSC as a treatment for 
glaucoma(13, 26). In their earliest study, BMSC were ivit transplanted into a laser-induced 
ocular hypertensive glaucoma model. The model yielded a 40% loss of RGC axons 28d after 
induction of glaucoma, which was reduced to a 10% after ivit BMSC transplantation. In the 
present study, our model yielded a Brn3a+ RGC loss of 33% which was reduced to an 18% 
loss when eyes received ivit transplantation of BMSC. Possible explanations for why BMSC-
mediated neuroprotection was 30% in a previous study(13) and only 15% in the present 
study may be that: A), the present study used a different model of glaucoma which results in 
less RGC death and thus less potential for neuroprotection, and B), the present study 
counted Brn3a+ RGC whereas the Johnson et al, counted axons within the optic nerve, 
whose death precedes the loss of the RGC soma and will therefore yield greater disparities 
between treatment and control groups. A more recent study(27) has explored the use of 
BMSC as a treatment for open angle glaucoma and demonstrated a 17% increase in the 
survival of RGC, similar to the 15% neuroprotection observed in this study. However, the 
authors injected hyaluronic acid IC to elevate IOP instead of TGF-β (and thus this was a 
model of acute rather than chronic open angle glaucoma) and used animal-derived BMSC 
instead of human-derived as was used in the present study. 
As well as counting RGC somata we used OCT to measure the thickness of the RNFL which 
reflects RGC axon loss. The RNFL is comprised of axons of the RGC as they course over 
the inner surface of the retina and towards the optic disc. Although axonal loss precedes 
RGC loss, the resolution of OCT is not as high as direct fluorescent microscopy making 
direct comparisons of the two measurements difficult. In addition, the RNFL contains 
astrocytes and retinal blood vessels and thus is not an absolute measure of RGC axon 
numbers. Despite this, we have previously shown that RNFL thickness is a reliable measure 
of moderate axonal loss but becomes inaccurate when the RNFL is substantially thinned (9). 
In the present study, RNFL thickness was reduced by 51% in the sham-treated 
glaucomatous eyes when compared to Intact controls. This is higher than the 33% loss in 
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RGC reported, and can be explained by fact that in glaucoma, RGC axonal loss precedes 
RGC loss and will thus is expected to be higher(28, 29). Indeed, although the pattern of 
neuroprotection as inferred from the RNFL thickness (i.e. DPSC being the most efficacious 
followed by BMSC and ADSC showing no neuroprotection) is the same as determined from 
Brn3a+ RGC counts, there is more retinal cell “death” recorded by RNFL thickness 
measurements than Brn3a+ RGC counts of the same group for the above reason. 
The present study did not explore the mechanisms by which MSC elicit neuroprotection of 
RGC in glaucomatous eyes, or why DPSC have greater therapeutic efficacy than 
BMSC/ADSC. However, previous published studies by us and others provided strong 
evidence for paracrine-dependent effects. Perturbations in retrograde axonal transport of 
NTF have been implicated in the pathology of glaucoma(3, 4) and explains the success of 
NTF supplementation as a neuroprotective strategy(9-13). We have previously shown that 
DPSC, BMSC and ADSC secrete multiple NTF including NGF, BDNF, NT-3, glial cell line-
derived neurotrophic factor, vascular endothelial growth factor and PDGF(10), whereas a 
recent paper demonstrated that PDGF(12) was a significant contributor to the 
neuroprotective effects elicited by BMSC on injured RGC. Our results corroborate this, 
demonstrating a significant ablation of the neuroprotective effects of DPSC, BMSC and 
ADSC when NTF receptors are blocked in culture(9, 10). As after optic nerve crush, the 
present study found that DPSC were the most RGC neuroprotective stem cells out of the 
tested MSC in our model of glaucoma which can be explained by their enhanced NTF profile 
in comparison to BMSC and ADSC(10), possibly due to the neural crest origin of DPSC (16). 
Our study did not find a neuroprotective effect of ADSC in this model of glaucoma. This is 
unsurprising given the reduced neurotrophic profile of ADSC in comparison to BMSC/DPSC, 
particularly since the neurotrophins BDNF and NT-3 showing no detectable expression(10). 
However, a recent previous study demonstrated a 19% RGC neuroprotective effect of ADSC 
after transplantation into the vitreous of an animal model of glaucoma(27). The disparity 
between the finding of this study and ours could be explained by: A), the use of a different 
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model of glaucoma focusing on closed angle glaucoma rather than open angle glaucoma; 
B), study duration of only 4 weeks in comparison to our 5 weeks; and C), the study used 
ADSC derived from rats whereas the present study used ADSC derived from humans. 
Finally, we measured the amplitude of the pSTR after ERG recordings on rats, using this as 
a measure of RGC function. A previous study(30) induced ocular hypertension in rats by 
injecting hypertonic saline into the episcleral vein, 5 times per week for 5 weeks. They 
demonstrated a 50% decrease in pSTR amplitude which correlated with both raised IOP and 
optic nerve damage. Our study demonstrated an 80-85% decrease in RGC function in sham-
treated glaucomatous eyes compared to Intact eyes, a more profound effect than the 
previous study, which could be due to the difference in the animal model used. Interestingly, 
pSTR amplitude showed a similar pattern to the Brn3a survival and OCT RNFL thickness 
data, with DPSC and BMSC promoting the most significant RGC survival/functional 
preservation and ADSC/sham-treated eyes showing the least. There is a profound 
neuroprotective effect of DPSC on RGC, with RGC numbers no different from that of an 
Intact eye, but less functional preservation, with pSTR amplitude in the DPSC group 
significantly lower than in Intact eyes. This observation suggests that DPSC significantly 
protect RGC from death and dysfunction in glaucoma, however a portion of surviving RGC 
may still be dysfunctional or destined to die at a later time point, likely because of the 
underlying raised IOP. Indeed, a previous study(31) demonstrated a significant 50% 
decrease in pSTR after only 75min of acute ocular hypertension (from 12mmHg to 60mmHg) 
suggesting, together with this study, that RGC function is more sensitive to raised IOP than 
is RGC survival. The data highlights the fact that IOP lowering drugs may still be a useful 
adjunct to a cellular neuroprotective therapy.  
Future work will focus on unravelling the precise mechanism for the paracrine-mediated 
neuroprotection of RGC and ensuring the safety of DPSC as a cellular therapy, for example, 
through the encapsulation of cells to prevent unwanted migration/proliferation(32), or the 
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genetic integration of a “suicide gene” to ensure cells can be selectively removed with 
ganciclovir after transplantation(33).  
5 Conclusions 
We demonstrate here for the first time the potential of DPSC to act as a cellular therapy for 
glaucomatous visual loss by protecting RGC and their axons from death and preserving 
RGC function. In comparison to BMSC and ADSC, DPSC were the most efficacious and 
thus may potentially represent an “ideal” cell to be trialled as a neuroprotective treatment for 
glaucoma.  
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 Figure 1 
Experimental design for the study. Time line of the in vivo experiment detailing when the 
stem cells were transplanted, glaucoma induction using bi-weekly injections of TGF-β and 
control animals using bi-weekly injections of PBS, ERG/OCT recording and day of animal 
culling. The group numbers and treatment regime for each eye are also given. 
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Figure 2 
IOP in rats injected with either TGF-β or PBS. IOP measurements (mmHg) from rats IC 
injected with bi-weekly TGF-β (red line) or PBS (blue line) and ivit injected with stem cells 
(see Figure 1.) Note the acute peak rise in IOP at 7d and the chronically maintained 
elevation from 14d and beyond, all time points are significantly different from each other 
(p<0.05) unless otherwise stated (NS; Not Significant), as determined using the generalised 
estimated equations (autoregressive correlation matrix). The PBS data is from 6 eyes in 6 
rats, whereas the TGF-β data is consolidated from the 4 treatment groups (12 rats, 24 eyes). 
Note that no significant differences in IOP were seen between the TGF-β injected groups 
transplanted with different MSC (not shown). 
 
Figure 3 
RNFL thickness after TGF-β-induced glaucoma in rats. OCT images of retina from an 
uninjured eye and a TGF-β-induced glaucomatous eye treated with ivit DPSC, BMSC, ADSC 
and dead DPSC (sham-treated) are shown (A) with red lines outlining the RNFL. The graph 
(B) depicts the RNFL thickness (µm) at 35d after glaucoma induction for the above 
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treatment groups as well as for uninjured eyes. Asterisks indicate significant difference from 
all groups where as black lines indicate significant difference between particular groups 
(p<0.05), as determined using a 1-way ANOVA and Tukey post-hoc test. Measurements 
were taken from images of sections containing the optic nerve head, indicated by the green 
line (C). Images and data representative from 5 animals/eyes per treatment group (scale 
bar: 200µm). 
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Figure 4 
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Brn3a+ RGC counts in standard radial eye sections. Immunohistochemically stained radially 
sectioned retina, stained for Brn3a (red), from Intact rats and rats IC injected with TGF-β for 
35d and also ivit transplanted with DPSC, BMSC, ADSC and dead DPSC (sham-treated). All 
images are representative of the 8 images taken per retina from 6 different animals (scale 
bar: 50µm). All images show tissues counterstained with the nuclear marker DAPI (blue). In 
(B), GFP+ MSC stained for the MSC marker Stro1 identified in the vitreous, adhered to the 
inner limiting membrane. In (C), the mean number of Brn3a+ RGC in a 1mm region of retina 
either side of the optic nerve head is shown from each of the above groups. Black lines 
indicate significant difference between groups (p<0.01), as determined using a 1-way 
ANOVA and Tukey post-hoc test.  
 
Figure 5 
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pSTR response after TGF-β-induced glaucoma. The mean amplitude of the pSTR response 
from the eyes of Intact rats and rats IC injected with TGF-β for 35d and also ivit transplanted 
with DPSC, BMSC, ADSC and dead DPSC (sham-treated) after a receiving a flash intensity 
of 3000mcd/s (A) and 1000mcd/s (B). Asterisks indicate significant differences between all 
groups whereas black lines indicate significant difference between groups (p<0.05), as 
determined using a 1-way ANOVA and Tukey post-hoc test. In (C), a representative image is 
shown of the ERG traces with an observable pSTR response from Intact rats and from rats 
IC injected with TGF-β for 35d with ivit transplantation of DPSC or dead DPSC, 6 different 
animals per group. 
 
 
